Using Monocyte Distribution Width to Improve Early Sepsis Detection

Multicenter trial confirms monocyte distribution width useful for early sepsis detection

Adverse clinical outcomes and higher costs correlate to delays in the timing of sepsis interventions during the early phases of the syndrome. Due to this correlation, novel protocols and biomarkers are being studied to improve detection time. A blinded, prospective cohort study conducted at three academic centers sought to validate the performance of monocyte distribution width (MDW)—which best revealed sepsis in an earlier feasibility study—for early sepsis detection in the emergency department (ED). The study compared the performance of MDW alone and in combination with white blood count (WBC), which is a commonly used clinical variable.

A total of 2,158 patients were enrolled in the study, of whom 385 met the diagnosis of Sepsis-2 while 243 displayed characteristics of Sepsis-3. A monocyte distribution width greater than 20.0 U distinguished sepsis from all other conditions based on either Sepsis-2 or Sepsis-3 criteria. The results of this study showed that MDW is effective for sepsis recognition during an initial emergency department visit and adds value to early sepsis detection.

Given that strong correlations between delayed treatment and higher mortality exist, improving early detection protocols is important for standardized sepsis care. The study exhibited how monocyte distribution width could enhance the clinical utility of the WBC and other SIRS (systemic inflammatory response syndrome) criteria for early sepsis detection in the ED.

Patient evaluation

Article Monocyte Distribution Width Adds Value to Early Sepsis Detection

Discover how a multicenter study validated monocyte distribution width as a novel indicator for Sepsis-2 and Sepsis-3 in high-risk emergency department patients.

Read article

Referenced In This Article

Crouser ED et al. "Monocyte Distribution Width: A Novel Indicator of Sepsis-2 and Sepsis-3 in High-Risk Emergency Department Patients." Crit Care Med 2019; 47(8):1018-1025.

Article featured in the Journal of Critical Care Medicine.

You may also be interested in:

Access SARS-CoV-2 IgG Antibody Test 
Laboratory studies show that to identify an immune response against the SARS-CoV-2 coronavirus, it is important to target the right antibodies. The Access SARS-CoV-2 IgG assay detects antibodies to the receptor-binding domain of the coronavirus spike protein, which may be important for assessing humoral and cellular immunity, based on laboratory studies. Learn more about this assay, which is available for Access 2, DxI 600 and DxI 800 immunoassay analyzers

Resources to Help in Navigating the SARS-CoV-2 Virus Pandemic 
The SARS-CoV-2 virus and the COVID-19 disease have disrupted the everyday lives of men, women and children around the world. Watch videos and access curated resources developed to help you in understanding, and managing, the SARS-CoV-2 virus pandemic.